Yeah, but what really happened? MRKR asked to clear up some paperwork, which happens frequently with the FDA, so that causes the stock to tank? Or was it the ovarian trial that apparently had little chance for success, to be discontinued in 2020 after a full data review.
This is pretty much the pancreatic fiasco all over again, nothing really negative but a half-assed effort to find anything positive, bringing the full wrath of 5m shorts.
By the way, the breast cancer data was really outstanding, my words not Peter's.
News 
Market Data 
Discover 
